Liminatus Pharma, Inc.
LIMN
$0.98
$0.077.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.29% | -- | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.29% | 372,633.33% | |||
| Operating Income | 37.29% | -372,633.33% | |||
| Income Before Tax | -1,709.36% | 37,866.67% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -1,709.36% | 37,866.67% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -1,709.36% | 37,866.67% | |||
| EBIT | 37.29% | -372,633.33% | |||
| EBITDA | 37.32% | -- | |||
| EPS Basic | -1,477.55% | -- | |||
| Normalized Basic EPS | -61.88% | -- | |||
| EPS Diluted | -1,477.55% | -- | |||
| Normalized Diluted EPS | -61.88% | -- | |||
| Average Basic Shares Outstanding | 15.91% | -10.43% | |||
| Average Diluted Shares Outstanding | 15.91% | -10.43% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||